Treatment For COVID-19: 30 Studies Are Under Way In France

30 studies are under way in France for treatment for COVID-19

In Paris, France, there are now 30 studies that are under way seeking the treatment for COVID-19, adding to the world total of 860.

Previously, a Filipino doctor shared the medicine they use for treating the new coronavirus. Rafael Castillo, MD said that hydroxychloroquine with azithromycin, tocilizumab, and high-dose melatonin could be game-changes in fighting against the COVID-19.

treatment for covid-19
📷: Food Navigator

On the other hand, Castillo admitted that tocilizumab and high-dose melatonin are not viricidal and that means they can’t kill the virus. However, these medicines can protect the organs of the body, especially the lungs that suffer the most from the deadly effects of the new coronavirus.

Medical experts from around the globe are also seeking possible drugs that would finally end the pandemic. Based on the report from ABS-CBN, 30 studies have started in France for the treatment of the said fatal disease.

 Infectologist Florence Ader said that 1,600 patients are involved in the “extremely active” research. As the head of the research, the infectious disease expert said that their study dubbed Discovery is collaborating with several countries in Europe.

coronavirus treatment
Photo credit: Thailand Medical News

Their research includes conducting clinical trials of four potential treatments.This involves the controversial hydroxychloroquine, which was also mentioned by Filipino doctor Rafael Castillo.

Among the 3,200 COVID-19 patients in Europe, about 800 of them are in France and all are severely-ill in hospitals. Ader added that this summer, the prestigious Institut Pasteur in France will carry the trials on humans.

Based on the report, there are almost 150 projects being conducted now around the globe to seek the development of a vaccine against the new coronavirus disease 2019.

What can you say about this?

READ ALSO: DILG Directs Brgy. Captains To Release Cash Aid Beneficiaries’ Masterlist

Leave a Comment